Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Panbela Therapeutics Inc (PBLA)

Panbela Therapeutics Inc (PBLA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 29,409
  • Shares Outstanding, K 13,429
  • Annual Sales, $ 0 K
  • Annual Income, $ -4,770 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 5.26
Trade PBLA with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.27
  • Number of Estimates 1
  • High Estimate -0.27
  • Low Estimate -0.27
  • Prior Year -0.21
  • Growth Rate Est. (year over year) -28.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.12 +3.30%
on 09/24/21
2.54 -13.78%
on 08/27/21
-0.02 (-0.90%)
since 08/24/21
3-Month
2.04 +7.35%
on 08/17/21
4.27 -48.76%
on 06/28/21
-1.36 (-38.31%)
since 06/24/21
52-Week
2.04 +7.35%
on 08/17/21
8.80 -75.11%
on 02/08/21
-0.75 (-25.51%)
since 09/24/20

Most Recent Stories

More News
Panbela to Present at Upcoming Investor Conferences

Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer today announced that it will present at...

PBLA : 2.19 (-4.37%)
CytRx Comments on Quarterly Results and Recent Strategic Initiatives

CytRx Corporation (OTCQB:CYTR) ("CytRx" or the "Company"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today commented...

PBLA : 2.19 (-4.37%)
CYTR : 0.6000 (+3.27%)
IBRX : 10.26 (-4.20%)
ORPH : 4.40 (-2.44%)
Panbela Provides Business Update and Reports Q2 2021 Financial Results

Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today provided a business update and...

PBLA : 2.19 (-4.37%)
Panbela Announces Issuance of key U.S. Patent; Patent is for Claims of a Novel Process for the Production of SBP-101

Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today announced an Issue Notification...

PBLA : 2.19 (-4.37%)
CytRx Announces Director Election Results from 2021 Annual Meeting of Stockholders

CytRx Corporation (OTCQB: CYTR) ("CytRx" or the "Company"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today...

PBLA : 2.19 (-4.37%)
DCTH : 9.85 (+1.13%)
LLY : 231.68 (-0.22%)
CYTR : 0.6000 (+3.27%)
IBRX : 10.26 (-4.20%)
ORPH : 4.40 (-2.44%)
Panbela Schedules Conference Call on August 11, 2021, to Report 2021 Second Quarter Financial Results

Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer today announced that it will host a conference...

PBLA : 2.19 (-4.37%)
50+ Companies to Present at the Access to Giving Virtual Investor Conference on July 13th - 15th, 2021

an investor conference themed around investor education and advocacy begins next week, July 13 - 15, 2021. More than 50 companies are scheduled to conduct virtual presentations over the three-day period...

ACOG.VN : 1.350 (-3.57%)
ACER : 2.56 (-0.97%)
ADXN : 9.70 (+1.31%)
AGRX : 1.0300 (unch)
ATGN : 2.0500 (-2.38%)
ABIO : 2.98 (-1.32%)
AUUD : 2.43 (-2.41%)
BASA : 0.3050 (-4.09%)
BMRA : 5.13 (+10.80%)
BKTI : 2.91 (+0.34%)
BSFC : 6.3000 (-1.56%)
DTST : 4.58 (-2.35%)
DCTH : 9.85 (+1.13%)
DMIFF : 0.2478 (+3.25%)
DLPN : 11.54 (-4.63%)
FLUX : 5.70 (-2.81%)
GBNH : 7.47 (-0.40%)
HAVLF : 0.2389 (-3.28%)
ISDR : 25.65 (-4.68%)
INLB : 1.6900 (+5.63%)
KNWN : 2.6375 (-1.95%)
LXXGF : 0.3200 (-2.26%)
MKTY : 8.18 (-2.62%)
MMATF : 13.6500 (-2.15%)
MRVFF : 1.0900 (unch)
NEPH : 9.10 (+4.24%)
NMTC : 4.18 (-1.18%)
NLSP : 2.59 (+1.97%)
OBLG : 2.20 (-1.79%)
PBLA : 2.19 (-4.37%)
POSAF : 0.9800 (-2.00%)
PCSA : 7.90 (+1.41%)
PTIX : 2.07 (+4.55%)
QOEG : 0.0999 (+41.50%)
QIPT : 5.90 (-1.17%)
SNGX : 1.0250 (-1.44%)
STRR : 2.57 (+0.78%)
TGCB : 0.7500 (unch)
VERB : 1.7900 (-3.76%)
WTEQ.CN : 0.105 (-4.55%)
WINT : 1.8900 (-0.53%)
AYRO : 3.60 (-1.10%)
BCTX : 9.19 (+10.99%)
BTX : 9.48 (-5.58%)
HWAL : 1.7520 (unch)
NMRD : 6.10 (+1.84%)
THBRF : 3.9500 (+2.60%)
TRIQ : 0.9399 (-1.06%)
Panbela to Present at Access to Giving Virtual Conference on July 15, 2021, at 10:30 a.m. ET

Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today announced that the company will...

PBLA : 2.19 (-4.37%)
PANBELA THERAPEUTICS ANNOUNCES CLOSING OF $10.0 MILLION BOUGHT DEAL OFFERING OF COMMON STOCK

Panbela Therapeutics, Inc. (Nasdaq: PBLA) (the "Company" or "Panbela"), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today announced...

PBLA : 2.19 (-4.37%)
PANBELA THERAPEUTICS INCREASES PREVIOUSLY ANNOUNCED BOUGHT DEAL OFFERING OF COMMON STOCK TO $10.0 MILLION

Panbela Therapeutics, Inc. (Nasdaq: PBLA) (the "Company" or "Panbela"), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today announced...

PBLA : 2.19 (-4.37%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Panbela Therapeutics Inc. is a clinical-stage biopharmaceutical company. It engages in developing disruptive therapeutics for patients with urgent unmet medical needs. The company's initial product candidate, SBP-101, is for the treatment of patients with metastatic pancreatic ductal adenocarcinoma,...

See More

Key Turning Points

3rd Resistance Point 2.47
2nd Resistance Point 2.38
1st Resistance Point 2.29
Last Price 2.19
1st Support Level 2.11
2nd Support Level 2.02
3rd Support Level 1.93

See More

52-Week High 8.80
Fibonacci 61.8% 6.22
Fibonacci 50% 5.42
Fibonacci 38.2% 4.62
Last Price 2.19
52-Week Low 2.04

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar